Nov 30, 2025, 14:49
Talha Badar ASH25 Key Abstracts to Watch in Acute Lymphoblastic Leukemia
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X:
“ASH25 Key abstracts to watch in acute lymphoblastic leukemia
Overall Takeaways — ASH 2025 ALL Landscape
Rapid movement toward chemo-free or chemo-lite regimens, especially in Ph+ ALL.
TKI + immunotherapy (blina / InO) emerging as new standard-contenders.
CAR-T earlier in therapy (CR1 consolidation and frontline).
Expanding roles for bispecifics and venetoclax-based combinations in R/R ALL.
MRD (especially NGS-MRD) central to future risk-adapted strategies.”
Discover the latest in Hemostasis Today.
-
Jan 26, 2026, 05:40Vicki Kopplin Offers Immediate Funding for People With Bleeding Disorders
-
Jan 26, 2026, 05:27Jill Storry on Alloimmune Hemolytic Disease of the Fetus And Newborn
-
Jan 26, 2026, 05:09Wathsala Manindrani Gives a A Practical Perspective on Red Cell Exchange Transfusion
-
Jan 26, 2026, 04:59Abdul Mannan: BDUC – 4 Letters That Make Many Haematologists Uncomfortable
-
Jan 26, 2026, 04:51Manoj Kumar Singh: Power In Me Foundation Celebrates 2026 as Year Of Rare
-
Jan 26, 2026, 04:40Heghine Khachatryan: Did You Know VWD Comprises 3 Main Types?
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE